Search results for "Interferon"

showing 10 items of 963 documents

Long-lasting remission of primary hepatic lymphoma and hepatitis C virus infection achieved by the alpha-interferon treatment

2004

Primary hepatic lymphoma is a rare but well-defined lymphoma entity that often pursues an aggressive clinical course. Most cases have been described in hepatitis C virus (HCV)-related chronic liver disease patients. Although anthracycline-based chemotherapy has been reported to be highly effective, the best therapeutic strategy has not been defined yet. The prognosis is dismal especially in patients treated with chemotherapy alone or when an advanced liver disease is present. Herein, we describe a case of primary hepatic large B-cell non-Hodgkin’s lymphoma, in a patient with HCV chronic infection. After a minor response with eight cycles of CHOP chemotherapy, a complete and sustained remiss…

Malemedicine.medical_specialtyalpha-interferonHepatitis C virusAlpha interferonCHOPChronic liver diseasemedicine.disease_causeGastroenterologyLiver diseasehemic and lymphatic diseasesInternal medicineremission primary hepatic lymphomaAntineoplastic Combined Chemotherapy Protocolsmedicinevirus infectionHumansUltrasonographyHematologybusiness.industryLymphoma Non-HodgkinLiver NeoplasmsRemission InductionInterferon-alphaHematologyHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseLymphomaLong-lastingImmunologyLymphoma Large B-Cell Diffusehepatitis Cbusiness
researchProduct

Androgen receptors and hormone sensitivity of a human prostatic cancer cell line (PC-3) are modulated by natural beta-interferon.

1994

Androgen receptors are expressed at a low level in the cell line PC-3, which does not respond to either androgens or antiandrogens. If these cells are exposed to natural beta-interferon (beta-IFN) a reduction in cell growth and an increase in androgen receptors, evaluated by both biochemical and immunocytochemical techniques, occur. This increase seems not to be related to a selective block of PC-3 in any phase of the cell cycle. Pretreatment with beta-IFN determines in PC-3 cells a partial responsiveness to the androgen dihydrotestosterone as reflected by the increase in cell number. Moreover, the antiandrogen hydroxyflutamide shows agonistic properties by increasing the cell number of PC-…

Malemedicine.medical_specialtymedicine.drug_classUrologyDrug Resistanceurologic and male genital diseasesAntiandrogenchemistry.chemical_compoundInternal medicinemedicineTumor Cells CulturedHumansCell growthCell CycleProstatic NeoplasmsAndrogen AntagonistsDihydrotestosteroneInterferon-betaCell cycleAndrogenImmunohistochemistryFlutamideAndrogen receptorEndocrinologychemistryCell cultureReceptors AndrogenDihydrotestosteroneAndrogensHydroxyflutamideCell Divisionmedicine.drugUrological research
researchProduct

Natural beta-interferon and androgen receptors in prostatic cancer cells.

1991

Both PC-3 and DU-145 cell lines are androgen-insensitive, but, in our experience, they contain androgen receptors (AR). Treatment of these cells with natural beta-interferon at a concentration of 1,000 IU/ml of culture medium determines an increase of AR (evaluated by a whole-cell assay), statistically significant with respect to control. Androgen unresponsiveness of our cells could be due to an AR level which is lower than that present in hormone-sensitive prostatic cancer cell lines, such as LNCaP cells. For this reason, interferon-promoted AR increase merits further investigation, even if other defects in receptor mechanism, responsible for hormone insensitivity, cannot be excluded.

Malemedicine.medical_specialtymedicine.drug_classUrologymedicine.medical_treatmenturologic and male genital diseasesCell LineProstateInternal medicinemedicineTumor Cells CulturedHumansβ interferonbusiness.industryProstatic NeoplasmsImmunotherapyAndrogenAndrogen receptorEndocrinologymedicine.anatomical_structureCell cultureReceptors AndrogenCancer cellInterferon Type IbusinessInterferon type Imedicine.drugUrologia internationalis
researchProduct

Genomic medicine reaches HCV-related liver transplantation: Hopes and clinical and public health implications

2011

Malemedicine.medical_specialtymedicine.medical_treatmentIL28BOLTLiver transplantationAntiviral therapyBioinformaticsHepatitismedicineHumansGenomic medicineHepatitisHepatologybusiness.industryInterleukinsPublic healthAntiviral therapyHepatitis C Chronicmedicine.diseaseLiver TransplantationImmunologyHCVInterferonFemaleInterferonsbusiness
researchProduct

Enhanced serum levels of soluble HLA class I molecules are induced by treatment with recombinant interferon-gamma (IFN-γ)

1991

SUMMARY In order to investigate serum levels of soluble HLA class I antigens after single injection of various doses of recombinant IFN-γ (rIFN-γ) and to correlate the changes observed to beta-2-microglobulin serum levels, we studied five patients with metastasizing renal cell carcinoma. Each patient received three treatment cycles of 10, 100 and 500 μg rIFN-γ three times at weekly intervals. The treatment cycles were separated by a therapy-free interval of 2 weeks. The order of dose levels was randomly assigned to each patient. Serum levels of soluble HLA class I proteins were measured by an ELISA in samples drawn immediately before and 4, 24, 48, 72 and 168 h after each administration of …

Malemedicine.medical_specialtymedicine.medical_treatmentImmunologyHuman leukocyte antigenlaw.inventionInterferon-gammalawInternal medicinemedicineHumansImmunology and AllergyInterferon gammaCarcinoma Renal CellKidneyDose-Response Relationship DrugBeta-2 microglobulinbusiness.industryHistocompatibility Antigens Class IRadioimmunoassayRecombinant Interferon GammaMiddle AgedRecombinant Proteinsmedicine.anatomical_structureCytokineEndocrinologySolubilityImmunologyRecombinant DNADrug Evaluationbeta 2-MicroglobulinbusinessResearch Articlemedicine.drugClinical and Experimental Immunology
researchProduct

ISDR pattern and evolution in patients with chronic hepatitis C treated with standard or Peg-IFN plus ribavirin

2003

The aim of the study was to characterize the interferon sensitivity determining region (ISDR) mutation pattern and its changes at 4 weeks of treatment in a population of patients infected with hepatitis C virus (HCV) genotype 1b receiving standard or PEG-IFN plus ribavirin (RBV), to find possible early correlates of therapy outcome.Forty-five patients with chronic hepatitis due to HCV 1b were treated by PEG-IFN-α2b (n=23) or IFN-α2b (n=22) plus RBV 1000–1200 mg/day. They were classified 24 weeks after stopping therapy as sustained responders (SR), relapsers (REL) or non-responders (NR). Sixteen patients were SR, 12 REL and 17 NR. ISDR mutations were evaluated by direct sequencing at baselin…

Malemedicine.medical_treatmentHepacivirusHepacivirusViral Nonstructural Proteinsmedicine.disease_causePolyethylene GlycolPolyethylene GlycolsCohort Studieschemistry.chemical_compoundInterferonMedicinePharmacology (medical)education.field_of_studybiologyRecombinant ProteinMiddle AgedRecombinant ProteinsTreatment OutcomeInfectious DiseasesDrug Therapy CombinationFemaleHumanmedicine.drugGenotypeHepatitis C virusMolecular Sequence DataPopulationInterferon alpha-2Antiviral AgentsVirusFlaviviridaeRibavirinHumansAmino Acid SequenceeducationAntiviral AgentPharmacologyChemotherapyHepacivirubusiness.industryRibavirinInterferon-alphaHepatitis C Chronicbiology.organism_classificationVirologychemistryMutationCohort StudiebusinessSequence Alignment
researchProduct

Targeting transcription factor Stat4 uncovers a role for interleukin-18 in the pathogenesis of severe lupus nephritis in mice

2011

Polymorphisms in the transcription factor Stat4 gene have been implicated as risk factors for systemic lupus erythematosus. Although some polymorphisms have a strong association with autoantibodies and nephritis, their impact on pathophysiology is still unknown. To explore this further we used signal transducers and activators of transcription 4 (Stat4) knockout MRL/MpJ-Fas(lpr)/Fas(lpr) (MRL-Fas(lpr)) mice and found that they did not differ in survival or renal function from Stat4-intact MRL-Fas(lpr) mice. Circulating interleukin (IL)-18 levels, however, were elevated in Stat4-deficient compared to Stat4-intact mice, suggesting that this interleukin might contribute to the progression of l…

Malemusculoskeletal diseasesMice Inbred MRL lprchronic inflammationLupus nephritisKidneyInterleukin-23ArticleProinflammatory cytokineOligodeoxyribonucleotides AntisenseGene Knockout TechniquesInterferon-gammaMiceimmune system diseasesmedicineAnimalsskin and connective tissue diseasesSTAT4DNA PrimersAutoimmune diseaseMice Knockoutlupus nephritisMice Inbred BALB CBase Sequencebusiness.industryGene Transfer TechniquesInterleukin-18InterleukinGlomerulonephritishemic and immune systemsSTAT4 Transcription Factormedicine.diseaseInterleukin-12chronic glomerulonephritisNephrologyImmunologyInterleukin 18FemalebusinessNephritisKidney International
researchProduct

Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register

2021

AbstractThe current study aims to compare injectable and oral first-line disease-modifying therapies (DMTs) for time to first relapse, time to confirmed disability progression (CDP), and time to discontinuation using a cohort of relapsing remitting multiple sclerosis (RRMS) patients, with data extracted from the Italian MS Register. This multicenter, observational, retrospectively acquired, and propensity-adjusted cohort study utilized RRMS-naïve patients from the Italian MS Register who started either injectable or oral first-line DMTs between January 1, 2010, and December 31, 2017, to evaluate the impact on disability outcomes in patients. Enrolled patients were divided into two groups, n…

Maleoral DMTsoral DMTAdministration OralDiseaseRelapsing-RemittingCohort Studies0302 clinical medicineImmunologicinjectable DMTPharmacology (medical)030212 general & internal medicineRegistriesSubcutaneousMiddle AgedItalyEDSS score; injectable DMTs; Multiple sclerosis; oral DMTs; real-world setting; Adjuvants Immunologic; Administration Oral; Adult; Cohort Studies; Female; Follow-Up Studies; Glatiramer Acetate; Humans; Immunologic Factors; Injections Subcutaneous; Interferon-beta; Italy; Male; Middle Aged; Multiple Sclerosis Relapsing-Remitting; Retrospective Studies; RegistriesAdministrationCohortSettore MED/26 - NeurologiaOriginal ArticleFemaleNeurosurgeryCohort studyOralAdultmedicine.medical_specialtyEDSS scoreInjections SubcutaneousLower riskInjectionsMultiple sclerosis03 medical and health sciencesMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicInternal medicinereal-world settingmedicineHumansImmunologic FactorsMultiple sclerosiAdjuvantsinjectable DMTsRetrospective StudiesPharmacologybusiness.industryMultiple sclerosisGlatiramer AcetateInterferon-betamedicine.diseaseDiscontinuationObservational studyNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection—A…

2013

International audience; Background & AimsTreatment of hepatitis C virus (HCV) infection with boceprevir, peginterferon, and ribavirin can lead to anemia, which has been managed by reducing ribavirin dose and/or erythropoietin therapy. We assessed the effects of these anemia management strategies on rates of sustained virologic response (SVR) and safety.MethodsPatients (n = 687) received 4 weeks of peginterferon and ribavirin followed by 24 or 44 weeks of boceprevir (800 mg, 3 times each day) plus peginterferon and ribavirin. Patients who became anemic (levels of hemoglobin approximately ≤10 g/dL) during the study treatment period (n = 500) were assigned to groups that were managed by ribavi…

Maleviruses[SDV]Life Sciences [q-bio]Hepacivirusmedicine.disease_causeGastroenterologyPolyethylene Glycolslaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled triallawErythropoiesisIncidenceGastroenterologyDisease Managementvirus diseasesAnemiaMiddle AgedRecombinant Proteins3. Good healthTreatment Outcome030220 oncology & carcinogenesisDrug Therapy CombinationFemale030211 gastroenterology & hepatologyAlgorithmsmedicine.drugmedicine.medical_specialtyGenotypeProlineSide effectAnemiaHepatitis C virusInterferon alpha-2Antiviral Agents03 medical and health sciencesInternal medicineBoceprevirRibavirinmedicineHumansErythropoietinDAADose-Response Relationship DrugHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C Chronicbiochemical phenomena metabolism and nutritionmedicine.diseasedigestive system diseasesSide EffectLogistic ModelschemistryErythropoietinImmunologyHemoglobinbusinessEPO
researchProduct

Managing hepatitis C in liver transplant patients with recurrent infection

2009

Tim Zimmermann1, Gerd Otto2, Marcus Schuchmann11Department of Internal Medicine, 2Transplantation Surgery, University of Mainz, GermanyAbstract: Hepatitis C virus (HCV) reinfection after liver transplantation (LT) and recurrent hepatitis C often lead to recurrent cirrhosis (RC). RC is one of the most frequent complications resulting in organ failure and early death after LT in HCV-positive patients with reported 5-year rates from 20% to 40%. As HCV-cirrhosis is one of the leading indications for LT, the therapeutic management is a central issue. To date, the best available therapy is a combination of pegylated interferon + ribavirin in patients with established recurrent hepatitis C proven …

Medicine (General)medicine.medical_specialtyCirrhosisHepatitis C virusmedicine.medical_treatmentLiver transplantationmedicine.disease_causeGastroenterologychemistry.chemical_compoundR5-920Pegylated interferonInternal medicinemedicineTransplantationmedicine.diagnostic_testbusiness.industryRibavirinHepatitis Cmedicine.diseaseSurgerychemistryTolerabilityLiver biopsyStatistics Probability and Uncertaintybusinessmedicine.drugTransplant Research and Risk Management
researchProduct